5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
S Vodenkova, T Buchler, K Cervena… - Pharmacology & …, 2020 - Elsevier
Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …
cancer (CRC) in the palliative and adjuvant settings. Over the past four decades, several …
[HTML][HTML] Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment
Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …
[HTML][HTML] Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Colorectal cancer (CRC) is the third most common tumour in men and the second in women,
accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and …
accounting for 10% of all tumour types worldwide. Incidence is 25% higher in males and …
Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors
K Ludford, WJ Ho, JV Thomas, KPS Raghav… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic
microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is …
microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is …
[HTML][HTML] Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
P Zhao, L Li, X Jiang, Q Li - Journal of hematology & oncology, 2019 - Springer
Immunotherapies have led to substantial changes in cancer treatment and have been a
persistently popular topic in cancer research because they tremendously improve the …
persistently popular topic in cancer research because they tremendously improve the …
[HTML][HTML] Difference between left-sided and right-sided colorectal cancer: a focused review of literature
Colorectal cancer is the third most common cancer worldwide with a high mortality rate at
the advanced stages. However, colorectal cancer is not a single type of tumor; its …
the advanced stages. However, colorectal cancer is not a single type of tumor; its …
Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer
F Pietrantonio, R Miceli, A Raimondi… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE In the CLASSIC and MAGIC trials, microsatellite instability (MSI)–high status was
a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant …
a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant …
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
M Chalabi, YL Verschoor, PB Tan… - … England Journal of …, 2024 - Mass Medical Soc
Background Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients
with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited …
with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited …
[HTML][HTML] Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by …
T Yoshino, D Arnold, H Taniguchi, G Pentheroudakis… - Annals of …, 2018 - Elsevier
The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …